The landscape of mRNA nanomedicine

Xiangang Huang; Na Kong; Xingcai Zhang; Yihai Cao; Robert Langer; Wei Tao

doi:10.1038/s41591-022-02061-1

The landscape of mRNA nanomedicine

Nat Med. 2022 Nov;28(11):2273-2287. doi: 10.1038/s41591-022-02061-1. Epub 2022 Nov 10.

Authors

Xiangang Huang^#¹, Na Kong^#^{1

2}, Xingcai Zhang^#³, Yihai Cao⁴, Robert Langer^{5

6}, Wei Tao⁷

Affiliations

¹ Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
³ School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
⁴ Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. yihai.cao@ki.se.
⁵ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
⁶ Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
⁷ Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. wtao@bwh.harvard.edu.

^# Contributed equally.

PMID: 36357682
DOI: 10.1038/s41591-022-02061-1

Abstract

Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer-BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed by recent progress in mRNA engineering and delivery. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Humans
Nanomedicine*
Proteins
RNA, Messenger / genetics

Substances

RNA, Messenger
Proteins